Human Microbiome Marketis valued atUSD 551.85 Million in 2021 nd is expected to reach USD 2107.81 Million by 2028;with a CAGR of 21.1% Over the forecast period.
The Human Microbiome Market report is segmented on the basis of product type, diseases, application, and region & country level. Based on product type, the global human microbiome market is classified as probiotics, prebiotics, symbiotics, and others. Based upon diseases, the global human microbiome market is classified into obesity, diabetes, autoimmune disorder, cancer, gastrointestinal disorders, central nervous system disorders, and others. Based upon application, the global human microbiome market is classified as therapeutics and diagnostics.
The human microbiome is the aggregate of all microbiota that resides on or within any of a number of human tissues and biofluids, including the skin, mammary glands, placenta, seminal fluid, uterus, ovarian follicles, lung, saliva, oral mucosa, conjunctiva, biliary, and gastrointestinal tracts. It includes; bacteria, archaea, fungi, protists, and viruses. As per recent estimates, a human body harbors microorganisms having a ratio of 3:1 compared to the number of human cells present. The relationship of most microbes with the human body ranges from being commensal and mutualistic to neutral and harmful.
Human microbiome-based therapies are available in the form of foods, prebiotics, diagnostic devices, probiotics, medical foods, drugs, and supplements. Technological advancements in metagenomics and next-generation sequencing have made microbiome-based testing easier and cheaper, and have led to the rapid analysis of the genomic content of microorganisms from human samples. This has boosted the development process for microbiome-based diagnostics.
The regions covered in this human microbiome market report are North America, Europe, Asia-Pacific, and the Rest of the World. On the basis of country level, a market of the Human Microbiome is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.
Global human microbiome market report covers prominent players like
The increasing incidences of lifestyle diseases are expected to drive the growth of the global human microbiome market. According to the World Health Organization, in 2016, 13% of the world population (adults) was obese. As per the New Era of Treatment of Obesity and Metabolic Disorders, published in 2016, microbes residing in the human gastrointestinal tract act as an endocrine organ, whose composition and functionality contribute to the development of obesity. However, stringent government regulations related to the approval of human microbiome-based therapies are creating a major weakness to the growth of the market. Moreover, growing investments by governments in the development of human microbiome-based therapies are creating abundant growth opportunities for the global market for the human microbiome.
North America is expected to dominate the global human microbiome market and held a major market share due to the growing funding and research and development activities by companies and research institutes in this region. The presence of a large number of players who are adopting various initiatives such as investment in research and development for the development of the new therapeutic area for the microbiome to prevent health issues such as irritable bowel syndrome, immune diseases, etc. is further contributing to the market in this region.
The Asia-Pacific market is anticipated to be the fastest-growing region for the human microbiome market attributed to the rising government funding in personalized medicine and the emergence of numerous initiatives to develop the human microbiome in countries such as China, Japan. These initiatives aim to optimize the methods for the assessment of the effect of the gut microbiome on human health through the standardization of protocols and procedures.
|Historical data||2015 - 2020|
|Forecast Period||2021 - 2028|
|Market Size in 2020:||USD 551.85 Million|
|Base year considered||2020|
|Forecast Period CAGR %:||
|Market Size Expected in 2028:||USD 2107.81 Million|
|Tables, Charts & Figures:||175|
|Human Microbiome Companies||Avidbiotics Inc., Avidbiotics Corp., 4D Pharma, Series Therapeutics, Second Genome, Enterome, Microbiome Therapeutics, LLC, Rebiotix Inc., Yakult Honsha Co., Ltd., Osel Inc., Vedanta Biosciences, Inc., Metabiomics Corporate, Synthetic Biologics, Inc., DuPont, BiomX Ltd., and others|
|Segments Covered||By Product Type, By Application, By Diseases|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us firstname.lastname@example.orgJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2023-24 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®